2017 Pediatric Rheumatology Symposium

May 17-20, 2017. Houston, Texas.

View by Number View by Title View Sessions

View by Date

Thursday, May 18, 2017

2:00PM-3:00PM: Abstract Number: 3

Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis: Results From an Open-Label, Long-Term Follow-up Study

Plenary Abstract Session 1

2:00PM-3:00PM: Abstract Number: 4

Microbiota-Dependent Signals Regulate Inflammatory Myelopoiesis in a Murine Model of Macrophage Activation Syndrome

Plenary Abstract Session 1

2:00PM-3:00PM: Abstract Number: 2

Murine Model of Arthritis Flare Identifies CD8+ Tissue Resident Memory T Cells in Recurrent Synovitis

Plenary Abstract Session 1

2:00PM-3:00PM: Abstract Number: 1

Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Improvement on Quality Measures for Children with Juvenile Idiopathic Arthritis

Plenary Abstract Session 1

4:45PM-5:15PM: Abstract Number: 15

An Internet-based Self-management Program for Adolescents with Juvenile Idiopathic Arthritis – A Randomized Controlled Trial

Clinical and Therapeutic Poster Breakout I

4:45PM-5:15PM: Abstract Number: 17

Anti-endothelial cell antibodies in juvenile dermatomyositis

Genetics and Pathogenesis Poster Breakout I

4:45PM-5:15PM: Abstract Number: 18

Bridging the gap between GWAS and mechanism in juvenile idiopathic arthritis using a novel high-throughput experimental screen

Genetics and Pathogenesis Poster Breakout I

4:45PM-5:15PM: Abstract Number: 24

Development and Implementation of a “Data-In-Once” Model for a Pediatric Rheumatology Learning Health System

Quality, Health Services and Education Research Poster Breakout I

4:45PM-5:15PM: Abstract Number: 14

Efficacy and Safety of Canakinumab in Patients with Periodic Fever Syndromes (Colchicine-Resistant FMF, HIDS/MKD and TRAPS): Results from a Phase 3, Pivotal, Umbrella Trial

Clinical and Therapeutic Poster Breakout I

4:45PM-5:15PM: Abstract Number: 21

Enhancing Quality of Care in Childhood-Onset Systemic Lupus Erythematosus by Improving Performance on Quality Indicator Measures in Cardiovascular and Bone Health

Quality, Health Services and Education Research Poster Breakout I

4:45PM-5:15PM: Abstract Number: 20

Enthesitis-Related Arthritis: Non-Peripheral Pattern is Associated with an Expansion of Peripheral Th17 Populations

Genetics and Pathogenesis Poster Breakout I

4:45PM-5:15PM: Abstract Number: 23

Impact of an Institutional Specialty Pharmacy on Adherence to Biologic Therapies

Quality, Health Services and Education Research Poster Breakout I

4:45PM-5:15PM: Abstract Number: 16

Novel Serum Broad-Based Proteomic Discovery Analysis Identifies Proteins and Pathways Dysregulated in Juvenile Dermatomyositis (JDM) Myositis Autoantibody Groups

Genetics and Pathogenesis Poster Breakout I

4:45PM-5:15PM: Abstract Number: 22

Patient perception of barriers to taking medication in Juvenile Idiopathic Arthritis

Quality, Health Services and Education Research Poster Breakout I

4:45PM-5:15PM: Abstract Number: 13

Prevalence of Celiac Antibodies and IgA deficiency in Juvenile Idiopathic Arthritis

Clinical and Therapeutic Poster Breakout I

1
2
3
…
10
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].